118 related articles for article (PubMed ID: 35026050)
1. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network.
Baldi GG; Lo Vullo S; Grignani G; Vincenzi B; Badalamenti G; Mastore M; Buonomenna C; Morosi C; Barisella M; Frezza AM; Provenzano S; Simeone N; Picozzi F; Mariani L; Casali PG; Stacchiotti S
Cancer; 2022 Apr; 128(7):1439-1448. PubMed ID: 35026050
[TBL] [Abstract][Full Text] [Related]
2. Imatinib in advanced chordoma: A retrospective case series analysis.
Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
[TBL] [Abstract][Full Text] [Related]
3. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
[TBL] [Abstract][Full Text] [Related]
4. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Lebellec L; Chauffert B; Blay JY; Le Cesne A; Chevreau C; Bompas E; Bertucci F; Cupissol D; Fabbro M; Saada-Bouzid E; Duffaud F; Feuvret L; Bonneville-Levard A; Bay JO; Vauleon E; Vinceneux A; Noel G; Penel N; Mir O
Eur J Cancer; 2017 Jul; 79():119-128. PubMed ID: 28478340
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of imatinib in advanced chordoma.
Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
[TBL] [Abstract][Full Text] [Related]
6. Phase II study on lapatinib in advanced EGFR-positive chordoma.
Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
[TBL] [Abstract][Full Text] [Related]
7. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network.
Stacchiotti S; Simeone N; Lo Vullo S; Baldi GG; Brunello A; Vincenzi B; Palassini E; Dagrada G; Collini P; Morosi C; Greco FG; Sbaraglia M; Dei Tos AP; Mariani L; Frezza AM; Casali PG
Cancer; 2021 Feb; 127(4):569-576. PubMed ID: 33107985
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.
Bishop AJ; Amini B; Lin H; Raza SM; Patel S; Grosshans DR; Ghia A; Farooqi A; Guadagnolo BA; Mitra D; Akdemir KC; Lazar AJ; Wang WL; Alvarez-Breckenridge C; Bird J; Rhines LD; Somaiah N; Conley AP
J Immunother; 2022 Oct; 45(8):374-378. PubMed ID: 35943386
[TBL] [Abstract][Full Text] [Related]
11. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
Al-Batran SE; Hartmann JT; Heidel F; Stoehlmacher J; Wardelmann E; Dechow C; Düx M; Izbicki JR; Kraus T; Fischer T; Jäger E
Gastric Cancer; 2007; 10(3):145-52. PubMed ID: 17922091
[TBL] [Abstract][Full Text] [Related]
12. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.
Callejo A; Faouzi S; Bouché O; Bertucci F; Chevalier T; Isambert N; Duffaud F; Collard O; Penel N; Terrier P; Mir O; Blay JY; Le Cesne A
Target Oncol; 2021 Jul; 16(4):485-492. PubMed ID: 34089444
[TBL] [Abstract][Full Text] [Related]
13. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
Adenis A; Ray-Coquard I; Italiano A; Chauzit E; Bui-Nguyen B; Blay JY; Tresch-Bruneel E; Fournier C; Clisant S; Amela EY; Cassier PA; Molimard M; Penel N
Br J Cancer; 2013 Nov; 109(10):2574-8. PubMed ID: 24149182
[TBL] [Abstract][Full Text] [Related]
14. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.
Schuetze SM; Bolejack V; Choy E; Ganjoo KN; Staddon AP; Chow WA; Tawbi HA; Samuels BL; Patel SR; von Mehren M; D'Amato G; Leu KM; Loeb DM; Forscher CA; Milhem MM; Rushing DA; Lucas DR; Chugh R; Reinke DK; Baker LH
Cancer; 2017 Jan; 123(1):90-97. PubMed ID: 27696380
[TBL] [Abstract][Full Text] [Related]
16. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
Liu C; Jia Q; Wei H; Yang X; Liu T; Zhao J; Ling Y; Wang C; Yu H; Li Z; Jiao J; Wu Z; Yang C; Xiao J
Lancet Oncol; 2020 Sep; 21(9):1244-1252. PubMed ID: 32888455
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia.
Nekoohesh L; Rostami S; Nikbakht M; Mohammadi S; Babakhani D; Alimoghaddam K; Ghahremani MH; Chahardouli B
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e1-e10. PubMed ID: 31718935
[TBL] [Abstract][Full Text] [Related]
18. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
20. Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months.
Lei C; Zhao B; Wang Q; Ge L; Wang H
J BUON; 2018; 23(2):460-467. PubMed ID: 29745093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
